Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
Also in the news, "renal denervation" shows promise as a treatment for high blood pressure; an estimated 17 million U.S. adults struggle with long-covid with no new treatments in sight; inequality ...